Objective: To explore the causative role of PCDH19 gene (Xq22) in female patients with epilepsy.
Mutations of protocadherin 19 (PCDH19) (Xq22) have been associated with epilepsy with mental retardation limited to females (EFMR) (OMIM#300088). 1,2 EFMR was originally described in a large pedigree with a unique sex-limited expression wherein affected females were connected through unaffected transmitting males. [3] [4] [5] Four new families were subsequently linked to chromosome Xq22. 1 EFMR is characterized by seizures beginning around 1 year of age and cognitive impairment. 1 Seizures are predominantly generalized but focal seizures have also been reported. In more than 50% of female patients, seizures are often associated with a febrile illness. 1 Early development is usually normal, followed by regression at seizure onset or later. Some patients manifest autistic features. 6 It has been emphasized that these features mimic Dravet syndrome (DS) in some patients. 7 The question of whether PCDH19 is a new gene for DS or just causes EFMR with DS-like features in some patients is still open.
We studied 117 female patients with febrile seizures and with a spectrum of epilepsy phenotypes including focal and generalized forms with either sporadic or familial distribution. PCDH19 screening showed point mutations in 13 probands (and 1 affected mother) exhibiting focal epilepsy or DS-like phenotypes, with or without mental retardation and autistic features. PCDH19 is thus emerging as a major gene for infantile-onset epilepsy in females.
METHODS Patient recruitment. To explore the causative role of PCDH19 in a spectrum of epilepsies with variable severity, we studied 117 female patients, either sporadic or familial, with a diagnosis of FS or focal or generalized epilepsy, with seizures beginning in infancy, childhood, or early adolescence, with or without mental retardation. We did not select probands based upon a particular pattern of familial distribution. Patients with structural, metabolic, or known genetic etiologies were excluded. Written informed consent was obtained from parents or guardians. The study was approved by the ethics committee.
Clinical assessment.
A detailed clinical history including prenatal and perinatal antecedents, age at seizure onset and semiology, occurrence of seizures precipitated by fever, genealogic information, cognitive functions, EEG recordings, and MRI were collected from the parents and/or other relatives of patients seen at the Child Neurology Unit of the Pediatric Hospital A. Meyer (Florence, Italy). For patients referred from other centers, medical records from child neurologists and other treating physicians were collected and reviewed whenever possible. Epileptic seizures and syndromes diagnoses were described according to the classifications of the International League Against Epilepsy. [8] [9] [10] The cohort was comprised of 70 patients who previously tested negative for SCN1A mutations and MLPA, includ-ing19 subjects with a clinical diagnosis of DS. 11 We also included 24 subjects who tested negative for CDKL5 mutations/deletions. 12 Mutation analysis. Blood samples were obtained from patients and parents. Genomic DNA was extracted using a DNA isolation robot (EZ1 DNA blood, Qiagen, Germany). The 6 exons covering the coding regions of PCDH19 (Entrez Gene, GeneID: 57526, accession number: EF676096.1) and their intron-exon boundaries were PCR-amplified and sequenced using the BigDye Terminator v.1.1 (Applied Biosystems, Foster City, CA). The first exon was amplified as a long fragment of 2.3 kb, sequenced using internal primers, and analyzed on the 3130XL DNA sequencers (Applied Biosystems). PCR/sequencing conditions are available on request. The PCDH19 alterations were not found in 190 ethnically matched control subjects and were described using the complementary DNA sequence EF676096.1.
X-inactivation studies. X-inactivation study was performed as previously reported. 12 X-inactivation was classified as random (ratio 50:50 to 80:20) or skewed (ratio Ͼ80:20). Table 1 summarizes the total number of patients included in the study and their epilepsy syndrome diagnosis. More than 80% (98/117) of patients had seizures beginning before 3 years of age.
RESULTS
PCDH19 mutation analysis. We found PCDH19 mutations in 13 of 117 probands (11%); table 2 summarizes the clinical characteristics of each patient. A mutation was also observed in the affected mother of patient 10 (table 2, patient 10a); thus there were 14 subjects with PCDH19 mutations. Mean age of probands at the time of study was 9 years.
Clinical characteristics of probands with PCDH19
mutations. Seizure history. Mean age at seizure onset was 8.5 months (median 8, range 4.5-19); in 8/13 probands (62%), FS were the presenting seizure type, with a mean age at onset of 11.5 months (median 9, range 4.5-19). Four patients (31%) presented with a cluster of partial seizures between 6 and 19 months of age; 1 patient had had a de novo afebrile status epilepticus (SE) at age 9 months. Recurrent convulsive SE had then occurred in 7/13 patients (54%) at a mean age of 36 months (median 14, range 8 -114) and was precipitated by fever in 3. Afebrile generalized TC seizures occurred in 10/13 patients (77%); mean age at onset was 13 months (median 15, range 9 -32). Other generalized seizures including absences and myoclonus occurred in 4/13 patients (31%); mean age at onset was 19 months (median 17.5, range 10 -29). Partial seizures were the most frequent seizure type, occurring in 12/13 patients (92%) at a mean age of 12 months (median 11, range 5-20).
Epilepsy. Seven of 13 patients (54%) had a diagnosis consistent with the DS spectrum (table 2, patients EEG studies. All patients had video-EEG recordings throughout the course of their epilepsy. Background activity was normal in 11/13 patients (85%) and slow in 2. Focal seizures from the centroparietooccipital regions were recorded in 5 patients (46%) and from the frontotemporal regions in 2 (figure 1). In 2 of them onset was consistently unilateral; in the remaining 5, independent onset from both sides was documented. In 2 patients, in addition to focal seizures, atypical absences and a generalized TC were also recorded. A lateralized hemiclonic (table 2) carried the missense substitution in a heterozygous fashion. We tested the parents and the proband using 8 polymorphic microsatellites confirming the pedigree structure (data not shown). The presence of a heterozygous mutation in the father might be explained by a duplication of the X chromosome region containing the entire or part of the PCDH19 gene. One mutation was inherited from a mother who had had epilepsy with afebrile generalized seizures beginning around 8 months of age (table 2, patient 10a). Her seizures were reported as convulsive (but a detailed semiology was unavailable) and recurred 2 to 3 times a year up until late childhood, despite treatment. At age 17 years, medication was withdrawn and she has been well since. Her cognitive functions were normal. There was also a family history of epilepsy in first-and second-degree relatives of 5 of 13 patients (38%). Epilepsy type of affected family members was not investigated further in 2 of 5 patients in whom PCDH19 mutations were de novo. Patient 11 (table 2) had a history of epilepsy in second-degree relatives of both the maternal and paternal sides of the family; patient 12 (table 2) had a history of epilepsy in second-degree relatives of the paternal side. SCN1A analysis had been performed in 9 of 12 patients prior to PCDH19 screening and was negative.
X-inactivation studies. Two patients had a skewed X-inactivation pattern (table 2: patients 1 and 12). Ten patients, including the mother of patient 10 (ta- ble 2), had a variable X-inactivation within the random pattern. For 2 patients, X-inactivation studies could not be performed.
PCDH19 mutations and genotype-phenotype correlations. Mutations were missense (6), truncating (2), frameshift (3), and splicing (2) . Eleven were new mutations. All missense mutations were localized in the extracellular domain; truncating/frameshift/splicing mutations were instead spread throughout the protein, including 4 located in the intracellular domain ( figure 2) .
A partial clinical overlap with the DS phenotype was observed in 7/13 patients (54%) with PCDH19 mutations. Overall, within the 19 patients with a clinical diagnosis suggestive of DS, who tested negative for SCN1A mutations, 7 (37%) had PCDH19 mutations.
Six patients (46%) had focal epilepsy beginning around 9 months of age with a cluster of focal seizures in 3 and with FS in 3. Epilepsy outcome in 4 such patients was rather favorable: 1 has been seizurefree for 2 years, 2 have isolated monthly seizures, and the fourth and youngest patient is seizure-free after an initial cluster. Of the remaining 2 patients with focal epilepsy, one, following a severe onset with SE, has, at present, monthly clusters of brief focal seizures, and one, the most severely affected, still has frequent clusters of focal seizures and afebrile SE (table 2, patients 13 and 6). Both latter patients developed autistic features in association with mental retardation. The distribution of missense mutations and the X-inactivation status did not appear to correlate with phenotypic differences, including degree of mental retardation, age at seizure onset, and epilepsy type or severity. However, 5/6 truncating mutations were associated with focal epilepsy. DISCUSSION We sought to ascertain the frequency of PCDH19 mutations in a cohort of female patients with a spectrum of epilepsy phenotypes. We identified mutations in 13/117 probands (11%) and in 3 parents including 2 unaffected fathers and a mother with generalized seizures in childhood.
Epilepsy phenotypes of probands carrying PCDH19 mutations could be classified in 2 forms: epileptic encephalopathy resembling DS in 7/13 patients (54%) and focal epilepsy in 6 (46%). We estimated that 7/19 of DS-like female patients (37%) who tested negative for SCN1A had PCDH19 mutations.
Depienne and coauthors 7 reported PCDH19 familial and de novo point mutations in 13 female patients with DS. A male patient with a similar phenotype carried a mosaic PCDH19 mutation. The authors estimated that 16% or 25%, if only female patients were included in the calculation, of their SCN1A-negative DS patients had PCDH19 mutations and that this gene might overall account for 5% of DS. Compared to classic DS with SCN1A abnormalities, patients with PCDH19 mutations had a slightly older age at onset (9.5 months), no photosensitivity, less frequent SE, absences and myoclonic seizures were also rare, and seizures were "less intractable." 7 In our cohort of DS-like patients, seizure onset was around 8 months, 43% had SE, 57% had either absences or myoclonus, and none was photosensitive. Seizures were intractable only in 1 patient, whereas the remaining 6 had yearly clusters including persistent yearly SE precipitated by fever in 1. All 7 DS-like patients had mental retardation that was mild in 4, severe in 3, and accompanied with autistic features in 2. Review of previously published clinical data and comparison with features observed in our patients clearly shows that phenotypic similarities between DS and PCDH19 mutated patients exist. Seizure onset before 1 year of age, often represented by FS, other subsequent seizure types precipitated by fever, and regression following seizure onset are overlapping clinical features. Peculiar in patients carrying PCDH19 mutations are the occurrence of seizures in clusters in almost all patients, frequent SE, and high frequency of focal seizures. Our PCDH19 patients had a milder outcome than DS; seizures become less frequent with age, whereas in DS, seizures typically remain refractory. Cognitive impairment also appears to be milder compared to DS. Among female patients in our cohort with early-onset focal epilepsies, 6/23 (26%) had mutations.
A recent study confirmed that PCDH19 mutations are found in females with infantile-onset epilepsy and mental retardation whereas patients with Rett syndrome or autism were negative, suggesting that PCDH19 is unlikely to be a significant contributor to these disorders. 6 In our cohort, autistic features in association with epilepsy and mental retardation were present in 6/13 (46%) patients.
In our study, mental retardation was not a constant feature of patients carrying PCDH19 mutations. Indeed, 2 of our probands with focal epilepsy and the affected mother of patient 10 (table 2) had epilepsy and normal cognitive abilities.
We analyzed a cohort of patients with different types of epilepsy collected from a pediatric neurology center, which implies an unavoidable bias toward more severe cases. We found de novo PCDH19 mutations to be overwhelmingly more frequent (10/13; 79%) . This finding indicates that de novo mutations are frequent when genetic testing is extended beyond the DS spectrum 7 to include milder cases. Of the 3 familial mutations we found, only 1 was inherited from an affected mother. The presence of a heterozygous PCDH19 mutation in an unaffected father is a novel finding, which might be explained by a duplication of the X chromosome region containing the entire or part of the PCDH19 gene.
PCDH19 mutations are predicted to lead to complete loss of function. 2 We identified 13 mutations: 6 missense, 2 truncating, 3 frameshift, and 2 splicing. Eleven are new mutations. Our results as well as previous reports indicate that truncating mutations are located throughout PCDH19, whereas pathogenic missense substitutions lay in the extracellular domain of the protein (figure 2). The p.Asn340Ser and p.Glu414Gln mutations affect residues belonging to calcium-binding motifs (figure e-1 on the Neurology Web site at www.neurology.org). 13 Residues p.His203; Phe206 and p.Thr404 are conserved among ␦ 2 PC-DHs (figure e-1) and belong to distinct ␤-strands of the EC2 and EC4 extracellular domains. 14 The p.Asp377 residue is strongly conserved among ␦ 1 and ␦ 2 PCDHs, suggesting a critical role in protein function. Therefore, these substitutions seem to either affect the calcium-binding activity or may alter the PCDH19 extracellular structure.
In our series, all patients with focal epilepsy carried truncating/frameshift/splicing mutations. This finding is difficult to explain and needs confirmation in larger series. To date, only missense polymorphisms such as the p.Arg958Gln or the p.Arg1107Gly have been identified in the intracellular domain of the protein, suggesting that this barely conserved domain better tolerates missense changes.
The biologic role of PCDH19 is unknown; this gene is expressed in developing brains of humans and mice, and is postulated to be involved in establishing neuronal connections and signal transduction at the synaptic membrane. 15, 16 Males are obligate carriers, and have no seizures and normal intellectual function. To explain this unique pattern of expression, a dominant negative effect of the mutant protein in carrier females or the presence of a compensatory rescue factor in males have been hypothesized. 5 The absence of PCDH19 expression in males might be compensated upon PCDh11Y, a Y chromosome gene that is expressed in human brain. 2 However, the finding of a PCDH19 mosaic deletion in a severely affected male 7 does not support this hypothesis. An alternative hypothesis suggests that homozygous transmitting males will have a homogeneous population of PCDH19-mutant cells, whereas affected females are likely to be mosaics comprising PCDH19 mutant and PCDH19-wild type cells. Such mosaicism might interfere with cell-cell communication. 2 A similar mechanism was proposed for the craniofrontonasal syndrome CFNS (MIM 304110). 17 The X-inactivation process by which one of the 2 copies of the X chromosome present in female mammals is inactivated leads to mosaicism if a female is heterozygous for an X-linked gene which might modulate the phenotypic expression of the diseases. Following the hypothesis that PCDH19 only affects females, who are likely to be mosaics, we performed the X-inactivation study of patients carrying PCDH19 mutations but found no correlation between the X-inactivation status and phenotypic expression.
Our data confirm that patients with epileptic encephalopathies resembling DS and lacking SCN1A abnormalities should be tested for PCDH19 mutations. Girls with early-onset cryptogenic focal epilepsy, with or without seizures precipitated by fever, should also be tested. The spectrum of phenotypes associated with PCDH19 mutations is likely to be larger than currently recognized. A larger number of phenotype-genotype correlative studies are required in order to provide better insights for prognostic ad-vice and genetic counseling also including women with mild epilepsy in remission.
